Q3 2026
Oct 15, 2026
Johnson & Johnson shares fell 5.7% after earnings, despite 6% operational sales growth, as the call offered no clear evidence of a guidance cut or specific shortfall to explain the reaction. Management said the company remained on track to meet its 2026 outlook, but that reassurance may not have been enough to offset investor concerns not detailed in the available transcript.
Key takeaways
- Q3 operational sales grew 6%, which management said was ahead of analyst consensus; quarterly sales exceeded $25 billion.
- Innovative Medicine grew 7.9%. Oncology sales rose approximately 17%, while RYBREVANT sales increased 64%.
- Tremfya sales grew 68%; CAPLYTA reached $1 billion in year-to-date sales, and SPRAVATO grew 36%.
- Management said J&J was on track to meet 2026 guidance and exceed $100 billion in annual revenue for the first time.
- The supplied transcript ends during the MedTech discussion, so it does not provide the full segment results or CFO’s detailed guidance.
Q2 2026
Jul 17, 2026
Shares declined 1.5% following Johnson & Johnson’s Q2 earnings despite management’s positive tone, reflecting investor caution over modest MedTech growth and cautious outlook signals amid mixed momentum across segments.
Key takeaways
- Reported operational sales growth was 5.6% overall, with Innovative Medicine up 6.8% and MedTech growing only 3.6%.
- Oncology remains a key growth driver, led by DARZALEX exceeding $4 billion in sales and nearly 18% growth, alongside strong early adoption of ICOTYDE and robust growth from CARVYKTI, TECVAYLI, and TALVEY.
- Immunology showed impressive gains, with TREMFYA sales up 71% and successful expansion in indications like inflammatory bowel disease and myasthenia gravis.
- Neuroscience products CAPLYTA and SPRAVATO showed encouraging new patient starts and momentum following regulatory approvals.
- MedTech’s slower 3.6% growth and no further detail on margin expansion raised concerns about segment momentum in a competitive market environment.
Q1 2026
Apr 14, 2026
Johnson & Johnson delivered a robust Q1 2026 with 6.4% operational sales growth, driven by strong performances across its innovative pharma and MedTech segments, and raised full-year guidance toward $100 billion revenue.
Key takeaways
- Q1 revenue grew 6.4% annually, with Innovative Medicine up 7.4% and MedTech up 4.6%, reflecting broad-based momentum.
- Oncology led with 18% growth in DARZALEX and FDA approvals for TECVAYLI and CARVYKTI, expanding pipeline impact.
- Immunology sales surged 64%, driven by TREMFYA, and FDA approval of ICOTYDE positions the company for significant market share in immunology.
- MedTech’s cardiovascular segment showed strength in ablation and circulatory recovery, with innovative platforms like VARIPULSE and OMNYPULSE gaining traction.
- The company remains on track for $100 billion in 2026 revenue, with confidence in sustained double-digit growth through 2027.
Q3 2025
Oct 14, 2025
Johnson & Johnson's Q3 2025 performance demonstrates strong operational growth across its business sectors, with a 5.4% increase in sales, underscoring the company's successful innovation strategy and market resilience.
Key takeaways
- Innovative Medicine achieved operational sales growth of 5.3%, propelled by robust performance from 11 key brands, including a 40% surge in TREMFYA sales.
- MedTech saw even higher operational growth of 5.6%, fueled by improvements in all subdivisions and the planned separation of the Orthopaedics business to enhance focus on high-growth areas.
- Oncology sales rose nearly 20%, driven by market-leading products like DARZALEX and CARVICTI, which now stands as the most successful CAR T therapy launch globally.
- The FDA approval of Inlexo for bladder cancer treatment showcases J&J's innovative capabilities and solidifies potential $5 billion annual peak sales for the product.
- J&J is expanding its immunology portfolio, with a strong forecast for TREMFYA, which has gained significant market share within its first year of launch.